Further Information
NF-kappa-B inhibitor beta, NF-kappa-BIB, I-kappa-B-beta, IkB-B, IkB-beta, IkappaBbeta, Thyroid receptor-interacting protein 9, TR-interacting protein 9, TRIP-9, NFKBIB, IKBB, TRIP9
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL
(MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form the
NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins
(NFKBIA, MIM 164008, or NFKBIB), which inactivate NF-kappa-B by
trapping it in the cytoplasm. Phosphorylation of serine residues on
the I-kappa-B proteins by kinases (IKBKA, MIM 600664 or IKBKB, MIM
603258) marks them for destruction via the ubiquitination pathway,
thereby allowing activation of the NF-kappa-B complex. Activated
NFKB complex translocates into the nucleus and binds DNA at
kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or
5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G
purine; and Y is a C or T pyrimidine).
- Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
- Potter, C., et al. Ann. Rheum. Dis. 69(7):1315-1320(2010)
- Segat, L., et al. Vaccine 28(10):2201-2206(2010)
- McGeachie, M., et al. Circulation 120(24):2448-2454(2009)
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This NFKBIB antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 326-355 amino acids from the C-terminal region of human NFKBIB.
4793
NF-kappa-B inhibitor beta
NFKBIB
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
38 kDa
Q15653
57015399
This antibody is purified through a protein A column, followed by peptide affinity purification.
Cell Cycle,Immunology,Signal Transduction
Q15653
Optimal dilutions for each application to be determined by the researcher.